LifeVantage (LFVN) Corporation announced the completion of an international in vitro cell study that investigated the effects of its international formulation for the MindBody GLP-1 System, known as the MB System, on activating GLP-1 production. The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements for all other markets in which LifeVantage operates. The study on the international formula, similar to the one completed on the US formula prior to its launch, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFVN:
- LFVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- LifeVantage appoints Thompson as Chief Information, Innovation Officer
- Craig-Hallum bullish on LifeVantage, initiates with a Buy
- LifeVantage initiated with a Buy at Craig-Hallum
- LifeVantage announces results of third-party cell study of health weight stack